Universitätsklinikum Jena

Running trials

• Not yet recruiting

  Asciminib Frontline Risk Adapted

  NCT07804901· Phase 2· Source

• Recruiting

  Registry for Duchenne and Becker Muscular Dystrophy

  NCT07402122· Source

• Not yet recruiting

  Phase 2 trial of ARPI to AR-degrader (BMS-986365) switch for suboptimal PSA-response in mCSPC (eARly-SWITCH).

  2025-523672-23-00· Phase 2· Source

• Recruiting

  A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease

  NCT07499232· Phase 3· Source

• Recruiting

  Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

  NCT07176312· Phase 2· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

  NCT06782490· Phase 2· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Source

• Recruiting

  LEOPARD Training and Validation Data Collection Study

  NCT06675604· Source

• Recruiting

  A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

  NCT06298565· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer

  NCT06319820· Phase 3· Source

• Active, not recruiting

  Early Genetic Identification of Obesity

  NCT06239064· Source

• Recruiting

  Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

  NCT05665608· Source

• Recruiting

  CytOSorb TreatMent Of Critically Ill PatientS Registry

  NCT05146336· Source

• Active, not recruiting

  TRICuspid Intervention in Heart Failure Trial

  NCT04634266· Source

• Active, not recruiting

  A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

  NCT05070858· Phase 3· Source

• Recruiting

  A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients

  NCT04996433· Source

• Active, not recruiting

  SeQuent® SCB "All Comers" Post Market Clinical Follow-up (PMCF)

  NCT04470934· Source

• Active, not recruiting

  Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

  NCT04562389· Phase 3· Source

• Active, not recruiting

  The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

  NCT04192747· Source

• Active, not recruiting

  Pulmonary Artery Sensor System Pressure Monitoring to Improve Heart Failure (HF) Outcomes

  NCT04398654· Source

• Active, not recruiting

  Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

  NCT03947619· Source

• Recruiting

  SIOP RANDOMET 2017

  2023-508926-91-00· Phase 3· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Source

• Active, not recruiting

  Pazopanib Vs. Pazopanib Plus Gemcitabine

  NCT02203760· Phase 2· Source

• Active, not recruiting

  International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer

  NCT03386734· Source

• Active, not recruiting

  Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability

  NCT03333187· Phase 2· Source

• Recruiting

  Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)

  NCT03188874· Source

• Recruiting

  GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial

  NCT02872987· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Acute myeloid leukemia1 recruiting
• Bladder cancer1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Depression1 recruiting
• Duchenne muscular dystrophy1 recruiting
• Gastric and esophageal cancer1 recruiting
• Heart failure1 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Neuroblastoma1 recruiting
• Primary biliary cholangitis1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID

  NCT05911009· Phase 2· Source

• Completed

  A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)

  NCT05841030· Source

• Completed

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· Phase 2· Source

• Completed

  A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device

  NCT05670587· Source

• Completed

  ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions 2

  NCT05072730· Source

• Completed

  Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients

  NCT05282732· Source

• Completed

  Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens

  NCT05217927· Phase 4· Source

• Recruiting

  JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

  NCT04892173· Phase 3· Source

• Terminated

  Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)

  NCT04968184· Phase 3· Source

• Terminated

  Enhancing Ultrasound & Photoacoustic for Recognition of Intestinal Abnormalities

  NCT04456400· Source

• Terminated

  A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

  NCT04271475· Phase 3· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Source

• Completed

  Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer

  NCT03647969· Phase 2· Source

• Completed

  Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

  NCT03678753· Phase 3· Source

• Completed

  Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer

  NCT03353831· Phase 3· Source

• Completed

  A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

  NCT03283085· Phase 3· Source

• Recruiting

  A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.

  NCT03320304· Source

• Completed

  A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

  NCT02975934· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

  NCT03011372· Phase 2· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Source

• Completed

  ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

  NCT02891824· Phase 3· Source

• Completed

  Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses

  NCT02467270· Phase 2· Source

• Completed

  A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation

  NCT02444338· Source

• Completed

  Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

  NCT01644110· Phase 1/2· Source